Roivant Sciences Ltd. (ROIV)
2025-06-30 | 2024-12-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 2,170 | 9,018 | 4,475 | 55,132 |
| Selling, general and administrative (includes 39,144 and 41,192 of share-based compensation expense for the three months ended june 30, 2024 and 2023, respectively) | - | - | - | 148,519 |
| Acquired in-process research and development | - | - | - | - |
| Research and development (includes 11,099 and 10,532 of share-based compensation expense for the three months ended june 30, 2025 and 2024, respectively) | 152,919 | 141,595 | 143,073 | 133,208 |
| General and administrative (includes 71,079 and 36,841 of share-based compensation expense for the three months ended june 30, 2025 and 2024, respectively) | 134,019 | 141,545 | 202,881 | - |
| Cost of revenues | 154 | 259 | 234 | 3,978 |
| Total operating expenses | 287,092 | 283,399 | 346,188 | 285,705 |
| Gain on sale of telavant net assets | - | - | - | 110,387 |
| Loss from operations | -284,922 | -274,381 | -341,713 | -120,186 |
| Change in fair value of investments | -19,125 | -21,314 | 48,375 | 15,226 |
| Interest income | 48,322 | 61,851 | 69,773 | 72,127 |
| Change in fair value of liability instruments | -2,329 | 2,147 | 635 | - |
| Other expense, net | -11,208 | -2,816 | -1,453 | -1,825 |
| Gain on deconsolidation of subsidiaries | - | - | - | - |
| Change in fair value of debt and liability instruments | - | - | - | 118,202 |
| Interest expense | - | - | - | 13,399 |
| Loss from continuing operations before income taxes | -269,262 | -234,513 | -224,383 | 70,145 |
| Income tax expense | 4,649 | -25,568 | 12,458 | 12,655 |
| Loss from continuing operations, net of tax | -273,911 | -208,945 | -236,841 | - |
| Income from discontinued operations, net of tax | - | 327,020 | -43,083 | - |
| Net (loss) income | -273,911 | 118,075 | -279,924 | 57,490 |
| Net loss attributable to noncontrolling interests | -50,556 | -51,306 | -49,740 | -37,807 |
| Net (loss) income attributable to roivant sciences ltd | -223,355 | 169,381 | -230,184 | 95,297 |
| Basic (in shares) | 680,286,922 | 722,716,168 | 735,470,796 | 735,816,536 |
| Diluted (in shares) | 680,286,922 | 722,716,168 | 735,470,796 | 781,627,601 |
| Net (loss) income per common share (in dollars per share) | -0.33 | 0.23 | -0.31 | 0.13 |
| Net (loss) income per common share (in dollars per share) | -0.33 | 0.23 | -0.31 | 0.12 |